FN Clarivate Analytics Web of Science
VR 1.0
PT J
DE circulating tumor cells; circulating tumor DNA; liquid biopsy
ID CIRCULATING TUMOR-CELLS; BREAST-CANCER; FREE-DNA; PROGNOSTIC VALUE;
   MOLECULAR CHARACTERIZATION; NEOADJUVANT CHEMOTHERAPY; INDEPENDENT
   ENRICHMENT; CLINICAL-APPLICATIONS; RECEPTOR EXPRESSION; POOLED ANALYSIS
ER

PT J
DE pancreas cancer; circulating tumor DNA (ctDNA); circulating tumor cells
   (CTC); liquid biopsy; relapse/recurrence
ID LIQUID BIOPSY
ER

PT J
ID CIRCULATING TUMOR-CELLS; METASTATIC BREAST-CANCER; RESISTANT
   PROSTATE-CANCER; DNA LIBRARY PREPARATION; ANTI-EGFR THERAPY;
   LUNG-CANCER; PLASMA DNA; ACQUIRED-RESISTANCE; STRANDED-DNA;
   CLINICAL-APPLICATIONS
ER

PT J
DE Liquid Biopsy; plasma DNA tissue mapping; epigenome; copy number
   aberrations; cancer screening
ID CIRCULATING TUMOR DNA; COPY NUMBER ABERRATIONS; BARR-VIRUS DNA
ER

PT J
DE Liquid biopsies; Circulating tumor DNA; Plasma genotyping; EGFR
ID CIRCULATING TUMOR-CELLS; FACTOR RECEPTOR MUTATIONS; FREE DNA; EGFR
   MUTATION; PERIPHERAL-BLOOD; NSCLC PATIENTS; PLASMA DNA; OPEN-LABEL;
   PHASE-III; SERUM
ER

PT J
DE Pleural effusion; Pulmonary adenocarcinoma; EGFR mutation; Extracellular
   vesicles; Liquid biopsy
ID CIRCULATING TUMOR DNA; DOUBLE-STRANDED DNA; LUNG-CANCER; MUTATION;
   EXOSOMES; BLOOD
ER

PT J
DE Liquid biopsy; CTC; CtDNA
ID LIQUID BIOPSY; CARCINOMA; HEAD; DNA; PLASMA; BLOOD; TOOL
ER

PT J
DE liquid biopsy; circulating tumor cells; circulating tumor DNA;
   gastrointestinal cancer
ID CIRCULATING-TUMOR-CELLS; PANCREATIC-CANCER; PERIPHERAL-BLOOD;
   PERSONALIZED MEDICINE; PROGNOSTIC VALUE; GASTRIC-CANCER; DNA; SURVIVAL;
   PLASMA; KRAS
ER

PT J
DE microfluidics; solid-phase amplification; risk stratification; prostate
   cancer; liquid biopsy
ID PROSTATE-CANCER; DIGITAL PCR; MUTATIONS; PLASMA; DNA
ER

PT J
ID CIRCULATING TUMOR-CELLS; HEPATOCELLULAR-CARCINOMA; EXTRACELLULAR
   VESICLES; PROMOTER METHYLATION; EARLY RECURRENCE; DNA METHYLATION;
   BIOMARKERS; PLASMA; MICRORNAS; MICROPARTICLES
ER

PT J
ER

PT J
ID CIRCULATING TUMOR-CELLS; FREE DNA; EGFR; PCR; MANAGEMENT; ORIGIN; BLOOD;
   ASSAY
ER

PT J
DE Colorectal carcinoma; Liquid biopsy; Biomarker; Prognostic; Predictive
ID CIRCULATING TUMOR-CELLS; ANTI-EGFR THERAPY; FREE DNA; PROGNOSTIC
   BIOMARKER; EXTRACELLULAR VESICLES; CLINICAL VALIDATION;
   ACQUIRED-RESISTANCE; PROGRESSION-FREE; EARLY-DIAGNOSIS; FREE MICRORNAS
ER

PT J
ID CIRCULATING TUMOR-CELLS; PLASMA DNA; TREATMENT SELECTION; BIOMARKER;
   THERAPY; AR-V7; RNA; METHYLATION; ABIRATERONE; RESISTANCE
ER

PT J
DE cancer screening; EGFR testing; liquid biopsy
ER

PT J
DE SCLC; CDX; liquid biopsies
ID CIRCULATING TUMOR-CELLS
ER

PT J
DE Monitoring; minimal residual disease; liquid biopsy
ER

PT J
DE liquid biopsy; EGFR; NSCLC
ER

PT J
DE Liquid biopsy; ALK; ROS1; resistance; mutation
ER

PT J
DE PCR; T790M; liquid biopsy; ctDNA
ER

PT J
DE liquid biopsy; T790M; progression
ER

PT J
DE microRNA; liquid biopsy; early disease detection
ER

PT J
DE EGFR; liquid biopsy; NSCLC
ER

PT J
DE liquid biopsy; monitoring of EGFR TKI treatment; EGFR T790M mutation
ER

PT J
DE liquid biopsy; dynamic monitoring; ALK mutation
ER

PT J
DE next generation sequencing; non-small cell lung cancer; liquid biopsy
ER

PT J
ID CIRCULATING TUMOR-CELLS; BREAST-CANCER; LUNG-CANCER; FREE DNA; COPY
   NUMBER; FECAL DNA; PLASMA; TESTS; BIOMARKERS; MORTALITY
ER

PT J
DE Hepatocellular carcinoma; Liquid biopsy; Circulating tumor cells;
   Circulating tumor DNA
ID FETOPROTEIN MESSENGER-RNA; POLYMERASE-CHAIN-REACTION; ALPHA-FETOPROTEIN;
   PERIPHERAL-BLOOD; PROMOTER METHYLATION; QUANTITATIVE-ANALYSIS;
   INTRATUMORAL HETEROGENEITY; CANCER STATISTICS; EARLY RECURRENCE;
   LIVER-DISEASE
ER

PT J
DE bladder cancer; liquid biopsy; biomarkers
ID CIRCULATING TUMOR-CELLS; COMPLEMENT FACTOR-H; MICRORNA EXPRESSION
   SIGNATURES; VOIDED URINE CYTOLOGY; MESSENGER-RNA; FOLLOW-UP; UROTHELIAL
   CARCINOMA; BREAST-CANCER; PROTEIN BIOMARKERS; PLASMA DNA
ER

PT J
DE Advanced NSCLC; EGFR/T790M; Liquid Biopsy; Digital droplet PCR
ER

PT J
DE outcomes; non-small cell lung cancer; Liquid Biopsy; histopathology
ER

PT J
DE Biomarkers; Circulating tumor cell; Urooncology; Personalizing therapy
ID CIRCULATING TUMOR-CELLS; PERIPHERAL-BLOOD; FREE DNA; ABIRATERONE;
   SURVIVAL; AR-V7
ER

PT J
ID CIRCULATING TUMOR DNA; CELL LUNG-CANCER; BREAST-CANCER; PLASMA DNA;
   COLORECTAL-CANCER; DIGITAL PCR; FETAL DNA; MUTATIONS; ORIGIN; EGFR
ER

PT J
DE Liquid biopsy; Liquid biosources; NSCLC; Lung cancer; Diagnostic
   biomarker; Prognostic biomarker; Predictive biomarker; Resistance
   biomarker; TEPs; cfDNA; ctDNA; EVs; Exosomes; CTCs
ID CIRCULATING TUMOR-CELLS; METASTATIC BREAST-CANCER; FREE DNA; SERUM DNA;
   EDUCATED PLATELETS; 1ST-LINE ERLOTINIB; BLOOD-PLATELETS; OPEN-LABEL;
   PHASE-III; FOLLOW-UP
ER

PT J
DE cancer; circulating tumor cells; circulating tumor DNA; exosomes; liquid
   biopsy; targeted therapy
ID CIRCULATING TUMOR-CELLS; METASTATIC BREAST-CANCER; K-RAS MUTATIONS;
   RESISTANT PROSTATE-CANCER; METHYLATION-SPECIFIC PCR; LUNG-CANCER; FREE
   DNA; COLORECTAL-CANCER; PLASMA DNA; EGFR MUTATION
ER

PT J
DE liquid biopsy; uterine aspirate; circulating tumour cells (CTCs);
   circulating tumour DNA (ctDNA); exosomes
ID CIRCULATING TUMOR-CELLS; MOLECULAR CHARACTERIZATION; FREE DNA;
   CARCINOMA; BIOMARKERS; MUTATIONS; IDENTIFICATION; EXPRESSION;
   MANAGEMENT; SIGNATURES
ER

PT J
DE Liquid biopsy; Central nervous system; CNS; Cerebrospinal fluid; CSF;
   Brain tumor; Brain metastases; Circulating tumor cells; Circulating
   tumor DNA; ctDNA; cfDNA; CTC; RNA; miRNA
ID CIRCULATING TUMOR-CELLS; POTENTIAL NONINVASIVE BIOMARKERS; BREAST-CANCER
   PATIENTS; FREE DNA LEVELS; CEREBROSPINAL-FLUID; LUNG-CANCER;
   LEPTOMENINGEAL METASTASIS; INTRATUMORAL HETEROGENEITY; DISEASE
   PROGRESSION; BRAIN METASTASES
ER

PT J
DE cell-free DNA; germline mutation; liquid biopsy; hereditary cancer
   syndromes; pancreaticobiliary neoplasms
ID CELL-FREE DNA; BREAST-CANCER; TUMOR DNA; CLINICAL-ONCOLOGY;
   AMERICAN-SOCIETY; POLICY STATEMENT; MUTATIONS; BRCA2; PREVALENCE; UPDATE
ER

PT J
DE Circulating tumor cells; liquid biopsy; urological cancer
ID UROTHELIAL CANCER
ER

PT J
DE Colon cancer; Gene mutation; Genomic evolution; Liquid biopsy;
   Next-generation sequencing
ID CIRCULATING TUMOR DNA; CELL-FREE DNA; SEQUENCE VARIATION; BRAF
   MUTATIONS; LUNG-CANCER; KRAS; HETEROGENEITY; RADIOTHERAPY; CONCORDANCE;
   RESISTANCE
ER

PT J
ER

PT J
ER

PT J
DE T790M; liquid biopsy; re-biopsy; non-small cell lung cancer
ID CELL LUNG-CANCER; MUTATION; PLASMA; CHEMOTHERAPY; CRIZOTINIB; GEFITINIB;
   SYSTEM; DNA
ER

PT J
DE oral cancer; circulating tumour cells (CTCs); circulating tumour DNA
   (ctDNA); exosomes; liquid biopsy
ID SQUAMOUS-CELL CARCINOMA; CIRCULATING TUMOR-CELLS; MITOCHONDRIAL-DNA
   CONTENT; 20 MESSENGER-RNA; NECK-CANCER; MICROSATELLITE ANALYSIS;
   CLINICAL-APPLICATIONS; SALIVA DIAGNOSTICS; BREAST-CANCER; HEAD
ER

PT J
DE circulating tumor cells; single cell analysis; deep-sequencing; liquid
   biopsy; cancer diagnosis; cancer treatment
ID CIRCULATING TUMOR-CELLS; METASTATIC BREAST-CANCER; DIFFERENTIAL
   EXPRESSION ANALYSIS; RESISTANT PROSTATE-CANCER; RNA SEQUENCING DATA;
   FREE PLASMA DNA; SINGLE-CELL; LUNG-CANCER; COLORECTAL-CANCER; INTRATUMOR
   HETEROGENEITY
ER

PT J
DE Liquid biopsy; lung cancer; personalized medicine
ID METASTATIC BREAST-CANCER; CIRCULATING TUMOR-CELLS; BARR-VIRUS DNA;
   LYMPHOEPITHELIOMA-LIKE CARCINOMA; LUNG-CANCER; COLORECTAL-CANCER;
   PROMOTER HYPERMETHYLATION; EXTRACELLULAR VESICLES; FOLLOW-UP; PLASMA
ER

PT J
ER

PT J
ID CIRCULATING TUMOR-CELLS; BREAST-CANCER; EXOSOMES; DISEASES; BLOOD
ER

PT J
DE Liquid biopsy; Biomarker; Tumor marker; Cancer diagnostics
ID CIRCULATING TUMOR DNA; CELL LUNG-CANCER; BREAST-CANCER; EGFR MUTATIONS;
   PLASMA; EXOSOMES; BLOOD; BIOMARKERS; EVOLUTION; HETEROGENEITY
ER

PT J
ID CIRCULATING TUMOR DNA; METAANALYSIS
ER

PT J
DE Liquid biopsy; lung cancer; biomarkers; early detection; screening
ID CIRCULATING TUMOR-CELLS; COLORECTAL-CANCER; BREAST-CANCER; FREE DNA;
   CLINICAL-PRACTICE; AUTOANTIBODY TEST; EXOSOMES; BLOOD; SERUM;
   PROGRESSION
ER

PT J
ID CIRCULATING TUMOR-CELLS; PATIENTS RECEIVING BIOCHEMOTHERAPY; MINIMAL
   RESIDUAL DISEASE; METASTATIC BREAST-CANCER; COLORECTAL-CANCER; BRAF
   MUTATIONS; PERIPHERAL-BLOOD; LUNG-CANCER; CLINICAL-SIGNIFICANCE; DIGITAL
   PCR
ER

PT J
DE EGFR T790 M-positive NSCLC; Osimertinib; Progression; Liquid biopsy;
   Dose; Case report
ID CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS; EGFR MUTATION;
   ADENOCARCINOMA; RESISTANCE; GEFITINIB
ER

PT J
DE Liquid biopsy; Circulating tumor cells; ctDNA; Minimal residual disease;
   Early detection; Biomarker
ID CELL-FREE DNA; LUNG-CANCER; EVOLUTION; BLOOD
ER

PT J
ID ANTI-EGFR THERAPY; CELL LUNG-CANCER; COLORECTAL-CANCER;
   ACQUIRED-RESISTANCE; TISSUE BIOPSY; DIGITAL PCR; DNA; MUTATIONS; BLOOD;
   PLASMA
ER

PT J
DE Cancer; screening; liquid biopsy; early detection; circulating DNA;
   circulating tumor cell (CTC)
ID CIRCULATING TUMOR-CELLS; DNA COPY NUMBER; LUNG-CANCER;
   COLORECTAL-CANCER; MITOCHONDRIAL-DNA; BREAST-CANCER; PLASMA DNA;
   HEPATOCELLULAR-CARCINOMA; NONINVASIVE BIOMARKER; DIAGNOSTIC BIOMARKER
ER

PT J
DE Cancer; liquid biopsy; tumor biomarkers
ER

PT J
DE Cell-free DNA; circulating tumor cells; clinical trials; exosomes;
   liquid biopsy
ID CIRCULATING TUMOR-CELLS; METASTATIC BREAST-CANCER; FREE DNA;
   PROSTATE-CANCER; PHARMACODYNAMIC BIOMARKER; EXPRESSION; PLASMA; BLOOD;
   SURVIVAL; THERAPY
ER

PT J
ER

PT J
DE Epidermal growth factor receptor; NSCLC; Peptide nucleic acid-locked
   nucleic acid polymerase chain reaction clamp; Retrospective design;
   Tyrosine kinase inhibitor
ID GROWTH-FACTOR RECEPTOR; RANDOMIZED PHASE-3 TRIAL; 1ST-LINE TREATMENT;
   OPEN-LABEL; CHEMOTHERAPY; GEFITINIB; ADENOCARCINOMA; MULTICENTER;
   ERLOTINIB; AFATINIB
ER

PT J
DE Primary brain tumor; Liquid biopsy; Circulating tumor DNA; Glioma;
   Blood; Cerebrospinal fluid
ID CELL-FREE DNA; CENTRAL-NERVOUS-SYSTEM; CIRCULATING DNA; BREAST-CANCER;
   LUNG-CANCER; EXTRACELLULAR VESICLES; MUTATIONAL BURDEN;
   PERIPHERAL-BLOOD; MISMATCH-REPAIR; PLASMA
ER

PT J
DE liquid biopsy; cell-free DNA; ctDNA; circulating tumor cell; cancer;
   screening; blood
ID CELL-FREE DNA; CIRCULATING TUMOR-CELLS; HEPATOCELLULAR-CARCINOMA
   PATIENTS; K-RAS MUTATIONS; FREE PLASMA DNA; ACQUIRED-RESISTANCE;
   PROGNOSTIC VALUE; DISEASE PROGRESSION; SERUM DNA; NONINVASIVE DETECTION
ER

PT J
DE Liquid biopsy; Bronchoalveolar lavage fluid; Extracellular vesicles;
   EGFR mutant DNA; Non-small cell lung cancer
ID PANCREATIC-CANCER; LUNG-CANCER; TUMOR-DNA; EXOSOMES; PLASMA; KRAS
ER

PT J
ER

PT J
DE Lung cancer; liquid biopsy; prognosis; treatment responses
ID CIRCULATING TUMOR-CELLS; DEFORMABILITY-BASED SEPARATION;
   CLINICAL-SIGNIFICANCE; BIOMARKER DISCOVERY; ACQUIRED-RESISTANCE;
   SENSITIVE DETECTION; MET AMPLIFICATION; PROTEOME ANALYSIS; PLASMA DNA;
   RNA
ER

PT J
DE Liquid biopsy; Circulating tumor DNA; Circulating tumor cells;
   Pre-analytical handling; Technology overview
ID CIRCULATING TUMOR-CELLS; LUNG-CANCER; RESIDUAL DISEASE; DNA; BLOOD;
   IDENTIFICATION; HETEROGENEITY; MUTATIONS; RECOVERY; SURVIVAL
ER

PT J
DE Circulating tumor cells; Cell-free nucleic acid; Exosomes; Liquid
   biopsy; Pancreatic cancer
ID CIRCULATING TUMOR-CELLS; DUCTAL ADENOCARCINOMA; NUCLEIC-ACIDS;
   BREAST-CANCER; FREE DNA; DISEASE PROGRESSION; EDUCATED PLATELETS;
   CLINICAL-RELEVANCE; PROSTATE-CANCER; PAN-CANCER
ER

PT S
ID CIRCULATING TUMOR-CELLS; METASTATIC BREAST-CANCER; LONG NONCODING RNAS;
   EPITHELIAL-MESENCHYMAL TRANSITIONS; EXTRACELLULAR VESICLE ISOLATION;
   DROPLET DIGITAL PCR; STAGE-III MELANOMA; LUNG-CANCER; FREE-DNA;
   PERIPHERAL-BLOOD
ER

PT J
DE EGFR; T790M mutation; liquid biopsy; COBAS ver2; PNA-LNA PCR clamp
   method; osimertinib
ID TYROSINE KINASE INHIBITORS; RANDOMIZED PHASE-3 TRIAL;
   ACQUIRED-RESISTANCE; OPEN-LABEL; 1ST-LINE TREATMENT; RE-BIOPSY; FREE
   DNA; GEFITINIB; ERLOTINIB; CHEMOTHERAPY
ER

PT J
ID METASTATIC COLORECTAL-CANCER; ADVANCED GASTRIC-CANCER; RAS GENE
   MUTATION; PANCREATIC-CANCER; PERIPHERAL-BLOOD; BREAST-CANCER; PLASMA
   DNA; PROGNOSTIC VALUE; LUNG-CANCER; MOLECULAR CHARACTERIZATION
ER

PT J
DE EGFR; NSCLC; SCLC transformation; 1790M; Liquid biopsy; ddPCR
ID CELL LUNG-CANCER; CIRCULATING TUMOR DNA; ACQUIRED-RESISTANCE; EGFR
   INHIBITOR; KINASE INHIBITORS; HETEROGENEITY; MECHANISMS; MUTATIONS;
   THERAPY; TKI
ER

PT J
DE Circulating Tumor Cells; Liquid Biopsy
ER

PT J
DE Cancer screening; cell-free DNA; circulating tumor cell; liquid biopsy;
   non-small cell lung cancer
ID NEEDLE-ASPIRATION-CYTOLOGY; TYROSINE KINASE INHIBITORS;
   ACQUIRED-RESISTANCE; TARGETED THERAPIES; JAPANESE PATIENTS; NSCLC
   PATIENTS; TISSUE BIOPSY; EGFR-TKIS; MUTATIONS; BLOOD
ER

PT J
DE Liquid biopsy; circulating tumor DNA (ctDNA); lung cancer; genetic
   sequencing
ID THERAPY
ER

PT J
DE liquid biopsy; circulating tumor cells; cell-free ctDNA; exosomes;
   precision medicine
ID CIRCULATING TUMOR-CELLS; RESISTANT PROSTATE-CANCER; METASTATIC
   BREAST-CANCER; NUCLEIC-ACIDS; FREE DNA; EXOSOMES; SURVIVAL; BLOOD;
   PROGRESSION; BIOMARKERS
ER

PT J
ID PD-1 BLOCKADE; LUNG-CANCER; DNA; SENSITIVITY; PROGNOSIS; BLOOD;
   LANDSCAPE; EVOLUTION; MELANOMA; TRIAL
ER

PT J
DE Ovarian cancer; Liquid biopsy; Circulating cell-free DNA; Circulating
   tumor DNA; Circulating tumor cell; Tumor biomarkers
ID PLATINUM-BASED CHEMOTHERAPY; RANDOMIZED CONTROLLED-TRIAL;
   PROGRESSION-FREE SURVIVAL; BONE-MARROW; PERIPHERAL-BLOOD; MOLECULAR
   CHARACTERIZATION; PROSTATE-CANCER; BREAST-CANCER; PLASMA DNA;
   PROGNOSTIC-SIGNIFICANCE
ER

PT J
DE peptide nucleic acid; biosensors; DNA; microRNA; liquid biopsy; cancer
ID CIRCULATING TUMOR-CELLS; METAL-ORGANIC FRAMEWORK; EFFECT TRANSISTOR
   BIOSENSOR; PLASMON RESONANCE SENSORS; CARBON NITRIDE NANOSHEET; LONG
   NONCODING RNAS; MICRORNA DETECTION; GOLD NANOPARTICLES; LIQUID BIOPSY;
   LUNG-CANCER
ER

PT J
ID PROSTATE-CANCER
ER

PT J
DE Next-generation sequencing; Liquid biopsy; ctDNA
ID CIRCULATING TUMOR DNA; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; CLONAL
   EVOLUTION; EGFR MUTATIONS; GENE-MUTATIONS; NSCLC PATIENTS; PLASMA;
   CRIZOTINIB; INHIBITOR
ER

PT J
DE Pulmonary fibrosis; Lung cancer; Liquid biopsy
ID REAL-WORLD; PIRFENIDONE; PROFILE; SAFETY; UPDATE; MULTICENTER;
   GUIDELINES; MANAGEMENT; EFFICACY; COHORT
ER

PT J
ID TUMOR DNA; EVOLUTION; LAPATINIB
ER

PT J
DE Lung cancer; cell-free DNA (cfDNA); epidermal growth factor receptor
   (EGFR); liquid biopsies
ID RESPONSE EVALUATION CRITERIA; KRAS MUTATIONS; OPEN-LABEL; INTERCALATED
   ERLOTINIB; 1ST-LINE ERLOTINIB; LIQUID BIOPSIES; EGFR MUTATIONS; ADVANCED
   NSCLC; COPY NUMBER; DIGITAL PCR
ER

PT J
ER

PT J
ER

PT J
DE Nipple aspirate fluid; Liquid biopsy; Breast cancer
ID TANDEM MASS-SPECTROMETRY; PROTEIN PROFILE ANALYSIS; PROTEOMIC ANALYSIS;
   HEALTHY WOMEN; SELDI-TOF; IDENTIFICATION; EXPRESSION; MICROENVIRONMENT;
   MS
ER

PT J
DE Cell-free DNA; liquid biopsy; lung cancer; next-generation sequencing;
   personalized medicine
ID CELL-FREE DNA; CIRCULATING TUMOR-CELLS; BLOOD-PLATELETS; MUTATIONS;
   RESISTANCE; DIAGNOSIS; PLASMA; EGFR; MICROPARTICLES; IDENTIFICATION
ER

PT J
ID CIRCULATING TUMOR DNA; 1ST-LINE CRIZOTINIB; CHEMOTHERAPY; RESISTANCE;
   NSCLC; CELLS
ER

PT J
ID CIRCULATING TUMOR DNA; CELL-FREE DNA; EGFR MUTATION; RESISTANCE;
   VALIDATION; MORTALITY; PLASMA; TRIAL; T790M
ER

PT J
ID 1ST-LINE CHEMOTHERAPY; ABIRATERONE; SURVIVAL
ER

PT J
ID CIRCULATING TUMOR-CELLS; METASTATIC BREAST-CANCER; SURVIVAL
ER

PT J
ER

PT J
DE NSCLC; liquid biopsy diagnostics; precision medicine; molecular markers;
   immunotherapy; antiangiogenic therapy
ER

PT J
ER

PT J
ID PANCREATIC ADENOCARCINOMA; QUANTIFICATION; MUTATION; UTILITY; PCR
ER

PT J
DE cell-free DNA; cerebrospinal fluid; liquid biopsy; metastasis;
   neoplastic meningitis; plasma
ID CEREBROSPINAL-FLUID; POOR-PROGNOSIS; KRAS MUTATION; COPY NUMBER; DNA;
   CANCER; CARCINOMA; INTEGRITY; PLASMA; SERUM
ER

PT J
ID BIOMARKERS; CARCINOMA; PROGNOSIS; NSCLC; CELLS
ER

PT J
ER

PT J
DE Liquid biopsy; circulating tumor cells; exosome; cell free tumor DNA;
   brain tumors
ID CEREBROSPINAL-FLUID; CANCER; CELL; DNA; GLIOBLASTOMA; GLIOMA;
   CIRCULATION; THERAPY; RNA
ER

PT J
DE Liquid biopsy; ctDNA; non-small cell lung cancer; clinical application;
   personalised medicine
ID CIRCULATING TUMOR DNA; ESMO CLINICAL RECOMMENDATIONS;
   ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; MUTATION ANALYSIS; EGFR
   MUTATIONS; OPEN-LABEL; PLASMA; CHEMOTHERAPY; HETEROGENEITY
ER

PT J
DE HER2; Breast cancer; Liquid biopsy; Personalized therapy; Oncolbx
ID CANCER; PACLITAXEL
ER

PT J
DE liquid biopsy; afatinib; digital PCR; Prospective study
ER

PT J
DE liquid biopsy; EGFR mutation
ER

PT J
DE molecular diagnostics; liquid biopsy; next generation sequencing
ER

PT J
DE Immunotherapy liquid biopsy; PD-L1 Circulating Tumor Cells; Circulating
   tumor cells; PD-L1 Liquid biopsy
ER

PT J
DE droplet PCR; circulating free DNA; liquid biopsy; next generation
   sequencing
ER

PT J
DE molecular profile; Driver Mutations; lung adenocarcinoma; liquid biopsy
ER

PT J
DE liquid biopsy; epidermal growth factor receptor (EGFR); non-small cell
   lung cancer (NSCLC)
ID EGFR MUTATIONS; TUMOR-DNA; GEFITINIB; PREDICTOR
ER

PT J
ID CIRCULATING TUMOR-CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; LABEL-FREE
   DETECTION; SINGLE-CELL; IN-VIVO; PERIPHERAL-BLOOD; FLOW-CYTOMETRY;
   BREAST BIOPSY; STEM-CELLS; TRANSCRIPTIONAL REGULATION
ER

PT J
DE Liquid biopsy; Circulating tumor cell (CTC); ctDNA; cfRNA; Exosomes
ID CIRCULATING TUMOR-CELLS; RESISTANT PROSTATE-CANCER; METASTATIC
   BREAST-CANCER; EDUCATED PLATELETS; PROGNOSTIC VALUE; BONE-MARROW; FREE
   DNA; BLOOD; RNA; BIOMARKER
ER

PT J
ER

PT J
DE Liquid-based endometrial cytology; Intrauterine sampling; SurePath (TM);
   Comparative study; Endometrial suction tissue biopsy
ID STROMAL BREAKDOWN; CONDENSED CLUSTER; CURETTAGE; CYTOMORPHOLOGY;
   DILATATION; WOMEN; PIPELLE; CELLS
ER

PT J
DE Liquid biopsy; Circulating tumor cells; Circulating free DNA; Exosomes
ID METASTATIC BREAST-CANCER; RADIATION-INDUCED CANCER; K-RAS MUTATIONS;
   LUNG-CANCER; COLORECTAL-CANCER; PANCREATIC-CANCER; PROGNOSTIC VALUE;
   PLASMA DNA; RANDOMIZED-TRIAL; PROSTATE-CANCER
ER

PT J
DE cancer surveillance; genomics; personalized medicine; liquid biopsy
ID CIRCULATING TUMOR DNA; CELL-FREE DNA; METASTATIC BREAST-CANCER;
   BLOOD-BASED ANALYSES; PLASMA DNA; COLORECTAL TUMORS; EGFR MUTATION;
   SERUM; HETEROGENEITY; MALIGNANCIES
ER

PT J
DE ctDNA; ctRNA; CTCs; exosomes; tumor-educated platelets; mutations; gene
   fusions; lung cancer
ID CIRCULATING TUMOR-CELLS; FACTOR RECEPTOR MUTATIONS; FREE DNA; EGFR
   MUTATIONS; MESSENGER-RNA; CLINICAL-SIGNIFICANCE; DIAGNOSTIC-ACCURACY;
   PROGNOSTIC-FACTOR; BLOOD-PLATELETS; NSCLC PATIENTS
ER

PT J
DE Urine; cell free DNA; cancer; liquid biopsy; markers
ID CIRCULATING TUMOR DNA; K-RAS DNA; BLADDER-CANCER; COLORECTAL-CANCER;
   LIQUID BIOPSIES; PROSTATE-CANCER; NUCLEIC-ACIDS; PLASMA; SERUM;
   METHYLATION
ER

PT J
DE Liquid biopsy; Free circulating DNA; Circulating tumor cells;
   Personalized medicine; Genomic alterations; Pathology
ID CIRCULATING TUMOR-CELLS; METASTATIC MELANOMA PATIENTS; LUNG-CANCER
   PATIENTS; FREE DNA; TARGETED THERAPIES; PERSONALIZED MEDICINE; MOLECULAR
   PATHOLOGY; ACQUIRED-RESISTANCE; EGFR MUTATION; SOLID TUMORS
ER

PT J
DE Biomarkers; extracellular RNA; liquid biopsy; cancer biomarkers; ExRNA
   Communication Program
ID COMMUNICATION CONSORTIUM; CIRCULATING MICRORNAS; PROSTATE-CANCER;
   NONCODING RNAS; DISEASE; CHALLENGES; BIOMARKERS; MARKERS; BIOPSY; PLASMA
ER

PT J
DE extracellular vesicles; translational medical research; cancer; exosome;
   biomarkers; targeted therapy; liquid biopsy; nanoparticles
ID BETA-GLOBIN
ER

PT J
DE Liquid biopsies; circulating tumor cells (CTCs); circulating tumor DNA
   (ctDNA); cell free DNA (cfDNA)
ID CIRCULATING TUMOR-CELLS; METASTATIC COLORECTAL-CANCER;
   PANCREATIC-CANCER; GASTRIC-CANCER; PERIPHERAL-BLOOD; BREAST-CANCER; FREE
   DNA; INTRATUMOR HETEROGENEITY; CETUXIMAB RESISTANCE; EXTRACELLULAR
   DOMAIN
ER

PT J
ER

PT J
DE Next-generation sequencing (NGS); non-small cell lung cancer (NSCLC);
   liquid biopsy; tyrosine kinase inhibitors (TKIs)
ID EGFR MUTATIONS; FREE DNA; TUMOR; ASSOCIATION; GEFITINIB; T790M; BLOOD
ER

PT J
ID CIRCULATING TUMOR-CELLS; EGFR MUTATION STATUS; LUNG-CANCER;
   PROSTATE-CANCER; NSCLC PATIENTS; DNA; PLASMA; HETEROGENEITY; SURVIVAL;
   THERAPY
ER

PT J
ID MARKERS
ER

PT J
ID CIRCULATING TUMOR-CELLS; METASTATIC BREAST-CANCER; NANOPARTICLE TRACKING
   ANALYSIS; FREE PLASMA DNA; EXTRACELLULAR VESICLES; PROSTATE-CANCER;
   NUCLEIC-ACIDS; INTRATUMOR HETEROGENEITY; MESENCHYMAL TRANSITION;
   COLORECTAL-CANCER
ER

PT J
DE exosomes; miRNA; exosomal isolation; NSCLC biomarker
ER

PT J
DE liquid biopsy; lung cancer; biomarkers; cell free DNA
ER

PT J
ER

PT J
DE Liquid biopsy; DNA methylation; ncRNA; cfDNA; epigenetic marker
ID CELL-FREE DNA; FREE CIRCULATING DNA; FREE PLASMA DNA; BREAST-CANCER
   PATIENTS; NON-CPG METHYLATION; FREE SERUM DNA; PROMOTER METHYLATION;
   LUNG-CANCER; HEPATOCELLULAR-CARCINOMA; PANCREATIC-CANCER
ER

PT J
ID CIRCULATING TUMOR-CELLS; RECEPTOR MUTATION STATUS; PLASMA DNA; EGFR
   MUTATIONS; ACQUIRED-RESISTANCE; COLORECTAL-CANCER; PROSTATE-CANCER;
   BREAST-CANCER; SURVIVAL; BIOMARKERS
ER

PT J
ER

PT J
ER

PT J
ER

PT J
ER

PT J
ER

PT J
DE Mutation; Breast cancer; Circulating tumor DNA; Plasma tumor DNA; Liquid
   biopsy; Translational research
ID CELL-FREE DNA; METASTATIC BREAST-CANCER; ESTROGEN-RECEPTOR-ALPHA;
   LUNG-CANCER; COLORECTAL-CANCER; MATERNAL PLASMA; ACQUIRED-RESISTANCE;
   ESR1 MUTATIONS; EGFR MUTATIONS; MICROSATELLITE ALTERATIONS
ER

PT J
DE Circulating tumor cells; Circulating tumor DNA; Metastatic breast
   cancer; Liquid biopsy
ID CIRCULATING TUMOR-CELLS; POOLED ANALYSIS; ESR1 MUTATIONS; NUCLEIC-ACIDS;
   DNA; SURVIVAL; DISEASE; CHEMOTHERAPY; THERAPY; MARKERS
ER

PT J
DE cfDNA; miRNA; Brain tumor; Liquid biopsy; Circulating tumor cells
ID BREAST-CANCER PATIENTS; HERPES-SIMPLEX ENCEPHALITIS;
   POLYMERASE-CHAIN-REACTION; CEREBROSPINAL-FLUID; MESSENGER-RNA;
   PERIPHERAL-BLOOD; MICRORNA EXPRESSION; BRANCHED EVOLUTION;
   COLORECTAL-CANCER; PROSTATE-CANCER
ER

PT J
ER

PT J
ER

PT J
DE CTCs; ctDNA; early detection; exosomes; liquid biopsy; minimal residual
   disease; NSCLC; personalized medicine; resistance monitoring; therapy
   options; tumor burden; tumor evolution
ID CIRCULATING TUMOR-CELLS; LUNG-CANCER PATIENTS; FREE DNA; EXTRACELLULAR
   VESICLES; EGFR MUTATIONS; PROGNOSTIC-SIGNIFICANCE;
   CLINICAL-IMPLICATIONS; EXOSOMAL PROTEINS; COLORECTAL-CANCER;
   GENE-MUTATIONS
ER

PT J
DE Circulating tumor DNA; Liquid biopsy; Intra-tumor heterogeneity; Disease
   monitoring; Molecular resistance; Early detection
ID CANCER-PATIENTS; BREAST-CANCER; ACQUIRED-RESISTANCE; INTRATUMOR
   HETEROGENEITY; COLORECTAL-CANCER; CIRCULATING DNA; EGFR BLOCKADE; PLASMA
   DNA; EVOLUTION; BIOMARKERS
ER

PT J
DE Precision medicine; Targeted therapy; Driver mutations; EGFR mutations;
   Response monitoring
ID CIRCULATING TUMOR DNA; METASTATIC BREAST-CANCER; COLORECTAL-CANCER;
   LUNG-CANCER; ACQUIRED-RESISTANCE; PROSTATE-CANCER; NEVER-SMOKERS;
   DIGITAL PCR; PLASMA DNA; BLOOD
ER

PT J
DE Circulating tumor cells (CTCs); breast liquid biopsy cancer
ID CIRCULATING TUMOR-CELLS; BREAST-CANCER; BONE-MARROW; MICROMETASTASES;
   SURVIVAL; DISEASE
ER

PT J
DE EML4-ALK; liquid biopsy; RT-qPCR; extracellular vesicles
ER

PT J
DE liquid biopsies; exosomes; miRNA analysis; molecular profile
ER

PT J
DE liquid biopsies; Curative treatment; NSCLC; EGFR mutations
ER

PT J
DE Circulating tumor cells; liquid biopsy; ALK rearranged lung cancer;
   whole genome sequencing
ER

PT J
DE Liquid biopsy; exosome; circulating tumor cell (CTC); cell free DNA
   (cfDNA); nucleic acids
ID CIRCULATING TUMOR-CELLS; RESISTANT PROSTATE-CANCER; METASTATIC
   BREAST-CANCER; FREE DNA; LUNG-CANCER; EXTRACELLULAR VESICLES;
   MESSENGER-RNA; PLASMA DNA; ACQUIRED-RESISTANCE; PANCREATIC-CANCER
ER

PT J
DE circulating tumor-derived DNA; EGF receptor; liquid biopsy;
   non-small-cell lung cancer; repeated biopsy; tumor heterogeneity;
   tyrosine kinase inhibitors
ID OPEN-LABEL; MUTATIONS; GEFITINIB; ERLOTINIB; ADENOCARCINOMA;
   CHEMOTHERAPY; MULTICENTER; RESISTANCE; THERAPY
ER

PT J
DE breast cancer; circulating tumor cells; liquid biopsy; tumor
   heterogeneity
ID LIQUID BIOPSY; PROGRESSION; SURVIVAL
ER

PT J
DE circulating biomarker; circulating tumor cell; CTC; epigenetics;
   exosomes; liquid biopsy; microRNA; NIPT; personalized medicine
ID CANCER
ER

PT J
DE brush biopsy; liquid-based cytology; slide-based cytology
ER

EF